ALPL抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using ALPL mouse mAb against HeLa (1), and NTERA-2 (4) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of MCF-7 cells using ALPL mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using ALPL mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Mouse kidney using ALPL mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rat kidney using ALPL mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Rabbit kidney using ALPL mouse mAb with DAB staining.    

  
  

The ALPL antibody targets alkaline phosphatase, tissue-nonspecific isozyme (ALPL), also known as tissue-nonspecific alkaline phosphatase (TNSALP). This enzyme, encoded by the ALPL gene, plays a critical role in mineralization processes by hydrolyzing phosphate esters to release inorganic phosphate. It is predominantly expressed in bones, liver, and kidneys, with distinct isoforms arising from post-translational modifications. ALPL dysfunction is linked to hypophosphatasia (HPP), a rare metabolic disorder characterized by defective bone mineralization due to mutations in the ALPL gene. Severe HPP manifests in infancy with skeletal abnormalities, respiratory complications, and seizures, while milder forms present in adulthood with osteoporosis or dental issues.

ALPL antibodies are essential tools in research and diagnostics. They enable the detection and quantification of ALPL protein levels via techniques like immunohistochemistry, Western blotting, or ELISA. These applications help elucidate ALPL's tissue-specific expression patterns, regulatory mechanisms, and its role in diseases such as HPP, chronic kidney disease, or cancer. In oncology, ALPL expression has been studied in hepatocellular carcinoma and osteosarcoma as a potential biomarker. Additionally, ALPL antibodies support therapeutic development for HPP, including enzyme replacement therapies or gene-targeted approaches, by monitoring treatment efficacy and ALPL activity restoration. Their specificity ensures accurate differentiation of TNSALP from other alkaline phosphatase isoforms in clinical assays.